Abstract 607P
Background
Melanoma brain metastasis has very poor prognosis, although recent treatment advances, including immune checkpoint inhibitors and targeted therapy, have improved the prognosis. We investigated the survival of Asian patients with melanoma brain metastasis and the effectiveness of radiotherapy and systemic therapies.
Methods
We retrospectively reviewed the survival rates of patients diagnosed with melanoma brain metastasis between January 2011 and December 2021 at the National Cancer Center Hospital in Tokyo, Japan. In addition, we identified factors associated with survival using Cox regression analysis.
Results
A total of 135 patients were included. The median overall survival after melanoma brain metastasis diagnosis was 7.8 months (95% confidence interval [CI] 6.1–9.6). The 6-month and 1-year survival rates were 60.7% and 34.8%, respectively. We identified the prognostic factors of melanoma brain metastasis, including non-acral primary location, low serum LDH levels, systemic therapy of single-agent immune check point inhibitors or targeted therapies, and radiotherapy of stereotactic irradiation. On the other hand, We found no significant difference in effectiveness between single-agent immune check point inhibitors, the combination of immune check point inhibitors, and targeted therapies.
Conclusions
We retrospectively investigated the survival of patients with melanoma brain metastasis at our facility. The survival of Asian patients with melanoma brain metastasis is relatively poor compared to that of Caucasian patients. Immune check point inhibitor, targeted therapy, and radiotherapy of stereotactic irradiation were associated with improved survival; however, we found no significant superiority of the combination of immune check point inhibitors over single-agent immune check point inhibitor or targeted therapy in terms of effectiveness. Further investigations using larger cohorts, multicenter analyses, and prospective studies are necessary to assess the effectiveness of systemic therapy in Asian patients with melanoma brain metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dermatologic oncology department in National Cancer Center Hospital.
Funding
Has not received any funding.
Disclosure
N. Yamazaki: Financial Interests, Personal, Advisory Board: Ono, Chugai; Financial Interests, Personal, Invited Speaker: Ono, Bristol Myers Squibb, Novartis, MSD, Maruho; Financial Interests, Institutional, Research Grant: Ono, Bristol Myers Squibb, Novartis, Amgen. K. Namikawa: Financial Interests, Personal, Advisory Board: MSD, Novartis; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Novartis, MSD, Ono. All other authors have declared no conflicts of interest.
Resources from the same session
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract